CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
The CCTG SC30 (RATIONAL) trial has been successfully funded through the CIHR fall competition for nearly $1.2 million over four years. The study will investigate treatment options for patients with blood cancers and low antibody levels to determine the best supportive care interventions to prevent serious infections.
The European Society for Medical Oncology (ESMO) has announced that the recipient of the 2025 TAT Honorary Award is Philippe Bedard, Professor of Medicine at the University of Toronto, Staff Medical Oncologist in the Division of Medical Oncology, Director of the Cancer Genomics Program, and a Principal Investigator in the Bras Drug Development Program at the Princess
Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre,open-label,multiarm, biomarker-directed,signal-seeking,umbrella,clinical trial for recurrent IDH mutant,grade 2/3 glioma
The 2024 - 2025 CCTG New Investigator Clinical Trial Practicum is now accepting applications!
The CCTG CO28 correlative study: Tumour-free ctDNA detection as a decision tool to support organ preservation in node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation, was presented by Dr Jonathan Loree at GI ASCO 2025. This oral abstract assessed circulating tumor DNA (ctDNA) in patients with T1-T3, N0 rectal cancer and found that ctDNA effectively identifies cancers with inadequate response to chemotherapy for which a more radical surgery is recommended.
